Parkinson's UK

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Lucy Therapeutics is a biotechnology company focused on developing innovative treatments for neurological diseases by targeting mitochondrial dysfunction. The company employs a unique approach to drug discovery, concentrating on drugging targets linked to the early stages of disease pathogenesis. This methodology not only addresses specific neurological conditions but also has the potential to extend treatment options for other related disorders, such as Parkinson's Disease and Alzheimer's Disease. Additionally, Lucy Therapeutics is dedicated to creating proprietary small molecule therapies and diagnostic biomarkers aimed at enhancing the understanding of the central nervous system. By leveraging advanced genetic technologies, the company aims to provide insights into personalized medicine, thereby improving patient outcomes and enabling more precise healthcare interventions.

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

The University of Nottingham is a leading, financially secure, campus-based institution renowned for its research, international outlook, and comprehensive academic offerings. It provides undergraduate sport courses and boasts a prestigious business school with campuses in the UK, China, and Malaysia, renowned for its influential research and strong corporate connections. The university is committed to internationalising its core activities, recruiting top students and staff globally, and preparing students for successful futures.

NRG Therapeutics is a drug discovery company established in 2018, specializing in therapeutic solutions aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and motor neuron disease. Founded by a team of professionals with extensive experience in the biotech and pharmaceutical sectors, the company focuses on developing brain-penetrant mitochondrial permeability transition pore inhibitors specifically for Parkinson's disease. NRG Therapeutics seeks to create innovative medicines that preserve mitochondrial function, thereby enabling effective treatment options for patients suffering from chronic neurodegenerative disorders.

NRG Therapeutics is a drug discovery company established in 2018, specializing in therapeutic solutions aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and motor neuron disease. Founded by a team of professionals with extensive experience in the biotech and pharmaceutical sectors, the company focuses on developing brain-penetrant mitochondrial permeability transition pore inhibitors specifically for Parkinson's disease. NRG Therapeutics seeks to create innovative medicines that preserve mitochondrial function, thereby enabling effective treatment options for patients suffering from chronic neurodegenerative disorders.

Keapstone Therapeutics Limited is a biotechnology company based in Sheffield, United Kingdom, that focuses on drug development targeting the Nrf2 signaling pathway for the treatment of Parkinson's disease and Motor Neuron Disease (MND). Established in 2017, the company is dedicated to developing a novel series of small molecule activators designed to enhance the therapeutic potential for patients with these neurodegenerative conditions. By preventing the interaction between KEAP1 and Nrf2, Keapstone's compounds aim to improve redox balance, support mitochondrial function, promote autophagy, and reduce inflammation, ultimately enhancing the quality of life for individuals affected by Parkinson's disease.